Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirjam de With

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancers|March 6, 2021
Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversyTessa A M Mulder, Mirjam de With, Marzia Del Re, et al.
Pharmacogenomics|December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanomaAndrew Kl Goey, Mirjam de With, Bram C Agema, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 15, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancerNiels Heersche, G D Marijn Veerman, Mirjam de With, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancerBodine P S Belderbos, Mirjam de With, Rajbir K Singh, et al.
Clinical Pharmacokinetics|September 16, 2023
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1Mirjam de With, Leni van Doorn, Esmay Kloet, et al.
Genes|April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer PatientsBram C Agema, Stijn L W Koolen, Mirjam de With, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 11, 2023
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDMirjam de With, Leni van Doorn, Demi C Maasland, et al.
JCO Precision Oncology|July 21, 2022
<i>DPYD*7</i> as a Predictor of Severe Fluoropyrimidine-Related Adverse EventsMirjam de With, Gemma Brufau, Laila A van den Berg, et al.
Cancers|April 3, 2021
Germline Variation in <i>PDCD1</i> Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapyMirjam de With, Daan P Hurkmans, Esther Oomen-de Hoop, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancers|March 6, 2021
Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversyTessa A M Mulder, Mirjam de With, Marzia Del Re, et al.
Pharmacogenomics|December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanomaAndrew Kl Goey, Mirjam de With, Bram C Agema, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 15, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancerNiels Heersche, G D Marijn Veerman, Mirjam de With, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancerBodine P S Belderbos, Mirjam de With, Rajbir K Singh, et al.
Clinical Pharmacokinetics|September 16, 2023
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1Mirjam de With, Leni van Doorn, Esmay Kloet, et al.
Genes|April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer PatientsBram C Agema, Stijn L W Koolen, Mirjam de With, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 11, 2023
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDMirjam de With, Leni van Doorn, Demi C Maasland, et al.
JCO Precision Oncology|July 21, 2022
<i>DPYD*7</i> as a Predictor of Severe Fluoropyrimidine-Related Adverse EventsMirjam de With, Gemma Brufau, Laila A van den Berg, et al.
Cancers|April 3, 2021
Germline Variation in <i>PDCD1</i> Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapyMirjam de With, Daan P Hurkmans, Esther Oomen-de Hoop, et al.
Pageof 2